The company specializes in molecular diagnostic tests that assess an individual's risk of developing disease, accurately diagnose disease, assess the risk of disease progression, and guide treatment decisions across six major medical specialties. Myriad Genetics is focused on maintaining leadership in the hereditary cancer market, diversifying its product portfolio, and increasing revenue from international markets. The company operates through two segments: diagnostics and other, which provides testing products and services to the pharmaceutical, biotechnology, and medical research industries. Myriad Genetics seeks to expand its business operations through mergers and acquisitions.